抗肿瘤药物的时间“罗盘”

2017-03-17 策力格尔 解药家庭药师

肿瘤现已成为严重危害人类健康的常见病,尽管药物在整个抗肿瘤治疗过程中占重要地位,已成为主要的治疗方法,但也不乏弊端。因为药物在杀伤癌细胞的同时,正常细胞也会受损,并伴随着恶心、呕吐、脱发、白细胞减少、免疫功能下降、骨髓抑制等。很多人难以承受这些痛苦,有的甚至放弃治疗。

肿瘤现已成为严重危害人类健康的常见病,尽管药物在整个抗肿瘤治疗过程中占重要地位,已成为主要的治疗方法,但也不乏弊端。因为药物在杀伤癌细胞的同时,正常细胞也会受损,并伴随着恶心、呕吐、脱发、白细胞减少、免疫功能下降、骨髓抑制等。很多人难以承受这些痛苦,有的甚至放弃治疗。

同一种药物,同一剂量,同一规格,同一批号,在一天中的不同时间服用,其疗效和毒性可能相差几倍,甚至几十倍。这在医学上称为“时辰药理学”。

人体的生理变化具有生物周期性,如肿瘤细胞和正常细胞具有不同的生物钟,肿瘤细胞在10时生长最旺盛,第2个生长高峰在22~23时,而正常细胞在16时生长最快。利用机体的昼夜节律改变,研究药物在体内代谢和排泄等昼夜节律性变化,确定最佳给药时间,引导患者合理用药,以下两组数据提供参考。

有研究报道,采用紫杉醇联合顺铂治疗85例晚期食管癌患者,将患者随机分为时辰组和常规组,两组患者均在使用化疗前给予水化利尿及止吐药等治疗。给药时间,有效率、毒副反应发生率比较见表1所示。

表1:时辰组与常规组在有效率,毒副反应发生率比较。


还有研究报道,选用多西他赛联合顺铂对130例晚期小细胞肺癌患者进行治疗,随机分时辰组与常规组,两组治疗方案相同,用药时间,有效率、白细胞下降率、消化系统不良反应及肝肾毒性见表2所示。

表2:时辰组常规组在有效率,毒副反应发生率比较。


更多研究发现,在乳腺癌等恶性肿瘤治疗中,时辰治疗患者耐受性更好,抗肿瘤效果更佳,在等剂量化疗药物上不良反应少,更显着提高患者生活质量。

新技术在用药时间上打破了早晨用药的常规,从而影响患者正常的生活规律及休息和睡眠等,我们作为治疗团队中的药师,要发挥专业特长,向患者及其家属详细介绍时辰化疗的科学性和优越性,让他们了解个体化治疗方案的内容、目的、及优越性等,消除患者疑虑和恐惧,鼓励他们树立战胜疾病的信心,使其融入家庭与社会。我相信,通过我们不断的努力,抗肿瘤时辰治疗,一定能够带来更好的治疗效果。到那时,我们也会面带微笑地和每一位肿瘤病人问好,握着他们的手,轻声地告诉她,“别怕,有我们在,一切的一切都会好起来的!”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=901338, encodeId=a0d99013382f, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e15437547, createdName=ms1000001975947593, createdTime=Mon Nov 23 08:23:55 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181646, encodeId=23b918164627, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Tue Mar 21 10:04:17 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446764, encodeId=38351446e649a, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537687, encodeId=6c43153e68715, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593678, encodeId=7cb915936e8a7, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180882, encodeId=8817180882da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sat Mar 18 12:42:03 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180615, encodeId=9b20180615f0, content=认真学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Mar 17 14:40:14 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
    2020-11-23 ms1000001975947593

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=901338, encodeId=a0d99013382f, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e15437547, createdName=ms1000001975947593, createdTime=Mon Nov 23 08:23:55 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181646, encodeId=23b918164627, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Tue Mar 21 10:04:17 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446764, encodeId=38351446e649a, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537687, encodeId=6c43153e68715, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593678, encodeId=7cb915936e8a7, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180882, encodeId=8817180882da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sat Mar 18 12:42:03 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180615, encodeId=9b20180615f0, content=认真学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Mar 17 14:40:14 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
    2017-03-21 卡圣

    感谢分享,学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=901338, encodeId=a0d99013382f, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e15437547, createdName=ms1000001975947593, createdTime=Mon Nov 23 08:23:55 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181646, encodeId=23b918164627, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Tue Mar 21 10:04:17 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446764, encodeId=38351446e649a, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537687, encodeId=6c43153e68715, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593678, encodeId=7cb915936e8a7, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180882, encodeId=8817180882da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sat Mar 18 12:42:03 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180615, encodeId=9b20180615f0, content=认真学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Mar 17 14:40:14 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=901338, encodeId=a0d99013382f, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e15437547, createdName=ms1000001975947593, createdTime=Mon Nov 23 08:23:55 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181646, encodeId=23b918164627, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Tue Mar 21 10:04:17 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446764, encodeId=38351446e649a, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537687, encodeId=6c43153e68715, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593678, encodeId=7cb915936e8a7, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180882, encodeId=8817180882da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sat Mar 18 12:42:03 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180615, encodeId=9b20180615f0, content=认真学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Mar 17 14:40:14 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=901338, encodeId=a0d99013382f, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e15437547, createdName=ms1000001975947593, createdTime=Mon Nov 23 08:23:55 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181646, encodeId=23b918164627, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Tue Mar 21 10:04:17 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446764, encodeId=38351446e649a, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537687, encodeId=6c43153e68715, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593678, encodeId=7cb915936e8a7, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180882, encodeId=8817180882da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sat Mar 18 12:42:03 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180615, encodeId=9b20180615f0, content=认真学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Mar 17 14:40:14 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=901338, encodeId=a0d99013382f, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e15437547, createdName=ms1000001975947593, createdTime=Mon Nov 23 08:23:55 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181646, encodeId=23b918164627, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Tue Mar 21 10:04:17 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446764, encodeId=38351446e649a, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537687, encodeId=6c43153e68715, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593678, encodeId=7cb915936e8a7, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180882, encodeId=8817180882da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sat Mar 18 12:42:03 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180615, encodeId=9b20180615f0, content=认真学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Mar 17 14:40:14 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
    2017-03-18 卡圣

    谢谢分享,学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=901338, encodeId=a0d99013382f, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e15437547, createdName=ms1000001975947593, createdTime=Mon Nov 23 08:23:55 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181646, encodeId=23b918164627, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Tue Mar 21 10:04:17 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446764, encodeId=38351446e649a, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537687, encodeId=6c43153e68715, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593678, encodeId=7cb915936e8a7, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Sun Mar 19 02:19:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180882, encodeId=8817180882da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Sat Mar 18 12:42:03 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180615, encodeId=9b20180615f0, content=认真学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Fri Mar 17 14:40:14 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
    2017-03-17 卡圣

    认真学习,谢谢分享

    0

相关资讯

2014年FDA新批准的抗肿瘤药物

年年月月花相似,岁岁年年花不同。每年美国FDA">FDA审评桌案上堆积如山的报批资料和争论不休的会议,也使审评加快了速度,速度与时间在赛跑,时间就是金钱,让人们充满了希望。 2014年,美国FDA药品评价和研究中心批准了41个新分子实体和生物制品许可申请。为过去18年之最。2014年美国FDA批准的41个新药中抗感染类药物有10个,而抗肿瘤领域也不示弱,仍达到了9个新药,而且获得美

今年将加快抗肿瘤等创新药审批工作

  国家食品药品监督管理总局药品审评中心化药一部副部长陈震昨日对记者表示,今年药品审评资源将继续向创新药物和重点领域仿制药审批倾斜,其中近期将重点加快抗肿瘤药、耐结核药等几类药物审评审批工作。   陈震是在出席国际制药工程协会中国年会期间作出上述表示的。据介绍,基于中国目前新药研发的基础和实力,通用名药即仿制药在今后相当长时期内仍将是我国医药卫生体系的支撑和基本保障,而随着人口老龄化、城镇化加速

未来5年畅销的抗肿瘤药物TOP10

随着肿瘤患者逐年增加,抗肿瘤药物市场也成为近年来医药界关注热点。最新统计显示,全球最畅销的100个药物中抗肿瘤药物有20个。下面来盘点一下未来5年最畅销抗肿瘤药物TOP10,其中既有风骚多年的罗氏三巨头单抗,有持续坚挺的来那度胺,有新型靶向小分子抗癌药物,更有近年来异军突起的PD1抑制剂类药物。TOP1 Revlimid 来那度胺来那度胺是新基(Celgene)开发的新一代抗肿瘤药,主

肿瘤药物研发大潮的驱动力及潜在风险

现在制药工业最热门的投资方向就是抗肿瘤药物研发,拒福布斯报道现在40%的新药研发经费投入到抗肿瘤药物上。那么这个比例是否合理呢?对厂家和投资方又有意味着什么呢? 前几天我们谈到80年代默沙东的辉煌,业界一致认为当时默沙东成为最盈利、最受社会尊重制药企业的主要原因是其科学驱动研发活动的战略。那么现在抗肿瘤药物这么高强度投入是否符合科学驱动原则?尽管基础研究也多年向抗肿瘤药物倾斜,但是这个领域的优质

Int Arch Occ Env HEA:加拿大卫生保健工作者暴露于抗肿瘤药物的风险因素

目的:本研究的目的是量化暴露在受管制的抗肿瘤药环境下加拿大卫生保健工作者非代谢环磷酰胺(CP) 的尿液浓度,确定与药物浓度水平相关的因素。 方法:参与者被要求提供两套24小时尿液样本(两个不同的抽样事件),使用高效液相色谱——质谱(即液质联用)量化CP的水平。除了人口统计信息外,调查参与者处理抗肿瘤药物的频率,药物安全处理培训,以及已知的接触CP的工作。描述性和推论性的进行统计分析。反向逐步的线

靶向抗肿瘤药物的命名

一个药物从研发到上市,通常都会有多个不同的名字。在研发阶段,药物通常会有一个或多个用来代表化合物的代号。研发成功后,药物会有一个通用名,上市销售时,制药公司会给予药物一个商品名。例如:小分子抑制剂“STI-571”就是后来众所周知的“伊马替尼”,诺华公司在市场推广的时候使用的商品名是“格列卫”。 一个靶向药物的通用名提供了这个药物的相关信息,比如类别及靶点。 单克隆抗体药物的通用名一般以“-m